RecruitingNCT07000110

Anifrolumab Malignancy and Serious Infections Study

A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab

Sponsor

AstraZeneca

Enrollment

3,195 participants

Start Date

Jan 26, 2026

Study Type

OBSERVATIONAL

Conditions

Systemic Lupus Erythematosus

Summary

This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.

Eligibility

Min Age: 18 YearsMax Age: 130 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Anifrolumab for people with systemic lupus erythematosus. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 130 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.